Dr Ian Osterloh

Ian Osterloh_edited.png

Dr Ian Osterloh is an experienced drug development executive, having held senior R&D positions in pharmaceutical companies such as Pfizer and the CMO role at a clinical-stage drug development company Ixchelsis focused on premature ejaculation.

In 1986, he joined the Research Division of Pfizer (Sandwich) and undertook various roles including Head of Clinical Regulatory Affairs and Head of Phase I Units. Fascinated by the experimental compound UK-92,480 (sildenafil), he stepped down from the latter role in order to design Phase II studies in the new indication of erectile dysfunction (ED). He led the clinical team, which designed and executed the Phase II/III trials for sildenafil for ED and subsequently the global candidate team seeing the product through to regulatory approval in the USA and Europe. He supported the investigation of sildenafil for other indications. In 2007, Dr Osterloh left Pfizer and set up his own consultancy company. He has contributed to a number of products in development for several pharmaceutical companies, including the role of Consulting Chief Medical Officer to Preglem up and until the European approval of ulipristal acetate for pre-operative treatment of fibroids.

Dr Osterloh graduated with first class honours in chemistry from Bristol University, subsequently studied medicine at Guy’s Hospital, London, and then undertook various hospital posts in the UK National Health Service, obtaining MRCP in 1985.